匹妥布替尼(Pirtobrutinib) - 药物靶点：BTK C481S_在研适应症：难治性小淋巴细胞淋巴瘤，难治性慢性淋巴细胞白血病，复发性慢性淋巴细胞白血病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

吡托布替尼、吡托布鲁替尼、LOXO-305

+ [7]

靶点

BTK C481S

作用方式

抑制剂

作用机制

BTK C481S抑制剂(酪氨酸蛋白激酶BTK C481S抑制剂)

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [2]

在研适应症

难治性小淋巴细胞淋巴瘤难治性慢性淋巴细胞白血病复发性慢性淋巴细胞白血病+ [18]

非在研适应症

原研机构

在研机构

+ [7]

非在研机构-

权益机构

Eli Lilly & Co.

信达生物制药

Redx Pharma Plc

+ [2]

最高研发阶段批准上市

首次获批日期

美国 (2023-01-27),

复发性套细胞淋巴瘤难治性套细胞淋巴瘤

最高研发阶段(中国)批准上市

特殊审评加速批准 (美国)、附条件批准 (中国)、孤儿药 (韩国)、优先审评 (美国)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C22H21F4N5O3

InChIKeyFWZAWAUZXYCBKZ-NSHDSACASA-N

CAS号2101700-15-4

关联

75

项与匹妥布替尼相关的临床试验

NCT07624799

/ Not yet recruiting临床2期IIT

Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL). A Phase II FILO Trial

The evidence base in support of fixed-duration, first-line approaches in medically fit patients with CLL is clearly strengthening, whether through combining targeted agents with immunochemotherapy or through chemotherapy-free combinations. The long-term PB MRD response rates with the investagators fixed-duration (15-month) immunochemotherapy approach remain the best to date, even compared to the new targeted agent combinations of ibrutinib-venetoclax or obinutuzumab-venetoclax.
The investigators' phase 2 ICLL07 trial in previously untreated fit CLL patients with a fixed-duration immunochemotherapy approach (with 4 cycles of FC-obinutuzumab and chemosparing strategy) carries a low risk for short and long term toxicities which still exist, including cardiac toxicities probably related to BTK inhibitors, moreover, two patients experienced treatment related myelodysplastic syndrome or acute myeloid leukemia beyond the end of treatment. Follow-up at 5,5 years from treatment start showed a persistent PB MRD benefit beyond end of treatment, high survival rates, and low long term toxicity with no difference in the durability of MRD response between the mutated and unmutated IGHV patients.
The investigators aim to explore the safety and efficacy of a fixed duration strategy combining a new BTK inhibitor with a favorable safety profile and a limited number of ICT courses.
The main goals and concerns are:
i) to ensure deep response and long lasting MRD ii) to reduce the duration of BTKi exposure and the risk of clonal evolution with the appearance of deleterious mutations iii) to limit the risk of hematopoietic secondary cancers (MDS/AML) by excluding patients in whom clonal hematopoiesis of undetermined potential (CHIP) is detected before inclusion and decreasing the number of courses of chemotherapy to 3 cycles. Moreover, patients with TP53 abnormalities will be excluded with a lower cut off (1% versus 10% in the previous studies) iv) to limit the risk of BTKi toxicity by using a non-covalent BTKi

开始日期2026-09-01

申办/合作机构-

CTIS2025-524842-89-00

/ Not yet recruiting临床2期IIT

HOVON 180 CLL: Prospective phase II trial of pirtobrutinib treatment (24 cycles) with 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. ODYSSEUS study (Outcome-Driven trial for relapsed CLL/SLL combining BTK and bispecific antibodY to improve outcome)

开始日期2026-09-01

申办/合作机构-

NCT07220187

/ Not yet recruiting临床3期IIT

A Randomized Phase III Study of Pirtobrutinib Plus R-CHOP vs. R-CHOP for Participants With Previously Untreated Richter Transformation (PIRAMID)

This phase III trial compares the effect of adding pirtobrutinib to the usual treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) to R-CHOP alone for the treatment of Richter transformation, which is when chronic lymphocytic leukemia or small lymphocytic lymphoma turns into large B-cell lymphoma, a more aggressive (faster-growing) form of lymphoma. Pirtobrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Adding pirtobrutinib to R-CHOP may kill more cancer cells than R-CHOP alone in patients with Richter transformation.

开始日期2026-08-31

申办/合作机构

SWOG

[+1]

100 项与匹妥布替尼相关的临床结果

登录后查看更多信息

100 项与匹妥布替尼相关的转化医学

登录后查看更多信息

100 项与匹妥布替尼相关的专利（医药）

登录后查看更多信息

197

项与匹妥布替尼相关的文献（医药）

2026-07-14·Blood Advances

Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cells

Article

作者: Guijosa, Alberto ; Hunter, Zachary R. ; Dhe-Paganon, Sirano ; Patterson, Christopher J. ; Castillo, Jorge J. ; Peachey, Abigail L. ; Hatcher, John M. ; Buhrlage, Sara J. ; Treon, Steven P. ; Liu, Shirong ; Wang, Jinhua ; Guerrera, Maria Luisa ; Branagan, Andrew R. ; Liu, Xia ; Pizzarella, Dominic ; Sarosiek, Shayna R. ; Kofides, Amanda ; Tsakmaklis, Nickolas ; Sun, Hao

2026-07-03·Expert Opinion On Drug Safety

Infectious complications associated with immune and targeted anti-cancer therapies: a retrospective study of the FDA adverse events reporting system (FAERS)

Article

作者: Alsowaida, Yazed S. ; Alsolami, Ahmed ; Abraham, Ivo ; Almangour, Thamer A.

BACKGROUND:

Immune and targeted anti-cancer therapies are associated with an increased risk of infectious complications. The objectives of the present study were to evaluate the infectious complications associated with immune and targeted anti-cancer drugs.

RESEARCH DESIGN AND METHODS:

This was a retrospective study for immune and targeted anti-cancer drugs submitted to the FDA Adverse Event Reporting System (FAERS) from 1996 to 20 March 2024. The primary outcome was the rate of infectious disease events, and the secondary outcomes were the incidence of febrile neutropenia (FN), all-cause mortality, and the top 10 infections in each class.

RESULTS:

Our study included 14 drug classes comprising 44 drugs. The incidence of infectious complications was 14.31% (110,671/773,130). The highest incidence rate was reported with IL-6 inhibitors (30.89%), the highest incidence of FN was reported with Histone deacetylase inhibitors (8.43%), and the highest all-cause mortality was reported with BCR-ABL tyrosine kinase inhibitors (17.17%).

CONCLUSION:

Immune and targeted anti-cancer therapies vary in the incidence of infectious complications. Pirtobrutinib, copanlisib, sirolimus, vorinostat, and tocilizumab were associated with high infectious complications (>30%) that warrant emphasis in the clinical guidelines. Thus, clinicians should vigilantly monitor patients undergoing immune and targeted therapies for infectious complications and use antimicrobial prophylaxes when indicated.

2026-07-01·AMERICAN JOURNAL OF HEMATOLOGY

Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single‐Cell Multi‐Omics

Article

作者: Lukas M. Simon ; Heng-Huan Lee ; Michael Wang ; Wei Wang ; Yijing Li ; Sairah Ahmed ; Joseph McIntosh ; Yue Fei ; Fangfang Yan ; Jovanny Vargas ; Yang Liu

ABSTRACT:

Pirtobrutinib (PBN), a non‐covalent BTK inhibitor, has been approved by the FDA for relapsed/refractory mantle cell lymphoma (MCL); however, resistance to PBN has been observed. To dissect the molecular dynamics driving PBN resistance, we performed integrative single‐cell multi‐omic profiling (scRNA‐seq, scATAC‐seq, and scDNA‐seq) on longitudinal MCL patient samples. Our analyses revealed both genetic and non‐genetic routes of resistance: In some patients, resistance involves sequential copy number gains (e.g., 1q, 2p, and 8q) accompanied by transcriptomic reprogramming and epigenetic alterations, whereas in others, resistance occurs through non‐genetic mechanisms driven by transcriptional and epigenetic remodeling. Integration of scATAC‐seq and scRNA‐seq enabled gene regulatory network inference and in silico perturbation analysis, highlighting RAD21 and SMC3, core components of the cohesin complex, as chromatin regulators whose downregulation may re‐sensitize cells to PBN. A stem‐like malignant B cell population enriched in resistant samples exhibited features of metabolic reprogramming and epithelial‐mesenchymal transition. Together, our findings highlight heterogeneous, multi‐layered mechanisms of PBN resistance and suggest chromatin regulators as potential therapeutic targets to overcome PBN resistance in MCL.

1,509

项与匹妥布替尼相关的新闻（医药）

2 小时之前

·药通社

重磅，国内刚上市新药，信达拿下！

8月10日，信达与第一三共宣布就维复泰®（盐酸奎扎替尼片）在中国的商业化达成独家许可协议。根据协议条款，第一三共将负责该药物的开发、生产和供应，而信达生物将独家拥有该产品在中国（大陆市场）的商业化权利，并主导市场推广。维复泰®刚刚于2026年6月在中国获得批准，用于联合标准阿糖胞苷和蒽环类药物诱导治疗以及阿糖胞苷巩固治疗，并在巩固化疗后作为单药维持治疗，用于治疗新诊断的、经充分验证的诊断方法检测为FLT3-ITD阳性的急性髓系白血病（AML）成人患者，该批准基于 QuANTUM-First 临床试验的结果。这是目前国内首款获批用于FLT3-ITD阳性新诊断AML一线治疗的FLT3抑制剂，也是第一个在中国获批的针对该高危亚型的靶向治疗药物。该药此前已在日本（2019年）、美国（2023年）和欧洲相继获批。在中国，2022年有近8.2万人被诊断出患有白血病，超过5万人因该病去世，白血病已成为中国第十大致死性癌症，而AML约占中国白血病病例的50%。在AML中，FLT3（FMS样酪氨酸激酶3）基因突变是最常见的突变类型，其中约80%为 FLT3-ITD 突变。FLT3-ITD突变见于约25%的AML病例中，它会驱动癌症生长，导致极差的预后，包括更高的复发风险和更短的总生存期。作为针对该靶点的创新药，Vanflyta®（quizartinib）是一种口服、高活性的II型FLT3抑制剂，可特异性针对FLT3-ITD突变。信达生物首席商业官、执行董事Vivian Zhang表示，此次合作是其血液学板块的重要里程碑，维复泰®将成为信达生物第20个商业化产品，进一步增强其在血液肿瘤领域的协同效应，此前该板块已拥有 TYVYT®（sintilimab注射液）、HALPRYZA®（rituximab注射液）、olverembatinib、FUCASO®（Equecabtagene Autoleucel注射液）以及 Jaypirca®（pirtobrutinib）等多元化产品组合。第一三共中国总裁Michio Hayashi也指出，此项合作结合了第一三共的研发能力与信达生物在中国强大的商业化能力，旨在加速VANFLYTA®在新诊断FLT3-ITD阳性AML患者中的应用，最终改善这一高危人群的治疗预后。值得一提的是，承接MNC核心产品的中国商业化权益，已成为信达生物近年来的标志性动作之一。 2026年6月30日，信达刚刚与礼来达成合作，获得CDK4/6抑制剂唯择®（阿贝西利片）在中国大陆的独家商业化权益，全权负责其进口、销售、推广与全渠道分销。业绩方面，8月5日，信达生物发布内幕消息公告，于2026年上半年，公司产品收入录得超人民币82亿元，同比增长55%以上；其中第二季度产品收入录得超过人民币43亿元，同比增长约60%。信达生物2024年82亿，2025年119亿，2026年直逼200亿——短短三年，信达生物完成了一场营收的“三级跳”，正处于高速发展阶段。免责提示：本文内容不涉及任何投资建议，投资需谨慎。 ↓⭐关注药通社，洞见行业趋势↓

上市批准申请上市

4 小时之前

·药圈头条

刚刚，信达生物与第一三共达成商业化合作！

刚刚，信达生物宣布，与第一三共（TSE：4568）就维复泰®（盐酸奎扎替尼片）在中国大陆市场的商业化达成独家委托推广协议。根据协议，第一三共将负责盐酸奎扎替尼片的临床开发、生产与供应，而信达生物取得盐酸奎扎替尼片在中国的独家推广权利，主导在中国市场的推广工作。盐酸奎扎替尼片是一种口服、高效II型FLT3抑制剂，选择性靶向FLT3-ITD突变，已于2026年 6月在中国获批：适用于治疗采用经充分验证的检测方法确定为携带FMS样酪氨酸激酶3内部串联重复（FLT3-ITD）突变的新诊断的急性髓系白血病（AML）成人患者。在诱导治疗期与标准剂量阿糖胞苷和蒽环类药物联合使用，在巩固治疗期与阿糖胞苷联合使用，并可在巩固治疗期后进行单药维持治疗。FLT3突变的检测要求参照【用法用量】。该批准基于 QuANTUM-First 试验结果。信达生物执行董事、首席商业官张倩女士表示：“此次与第一三共的合作，标志着我们在血液肿瘤业务板块迈出了令人振奋的一步。信达生物已在该领域持续拓展产品布局并形成强大的市场影响力，涵盖达伯舒®（信迪利单抗注射液）、达伯华®（利妥昔单抗注射液）、耐立克®（奥雷巴替尼片）、福可苏®（伊基奥仑赛注射液）、捷帕力®（匹妥布替尼片）等产品，而维复泰®（盐酸奎扎替尼片）的加入将进一步增强我们的协同效应。维复泰®也是信达生物商业化产品组合的第20款产品，我们期待通过双方合作，加速创新药物的开发与惠及，造福广大肿瘤患者，并进一步巩固我们在肿瘤治疗领域的领先地位。” 第一三共（中国）总裁林美智雄表示：“与信达生物达成的合作体现了我们致力于为中国患者带来创新的承诺。通过我们的研发能力与信达生物在中国的商业化能力相结合，期待这次的合作能加速新诊断 FLT3-ITD阳性AML患者获得维复泰®的机会，并最终帮助改善这一高风险患者人群的治疗结局。”

5 小时之前

·PRNewswire

Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China

Collaboration to accelerate access to Vanflyta® for patients with newly diagnosed FLT3-ITD positive AML SAN FRANCISCO and SUZHOU, China, Aug. 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Daiichi Sankyo (TSE: 4568), have entered into an exclusive agreement for the commercialization of Vanflyta® (quizartinib) in China. Under the terms of the agreement, Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta® while Innovent Biologics holds sole commercialization rights for Vanflyta® in China, leading market promotion. VANFLYTA was approved in China in June 2026 for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3-ITD positive as detected by an adequate validated diagnostic test, based on the results from the QuANTUM-First trial1. "This collaboration with Daiichi Sankyo represents an exciting milestone for our hematology franchise. Innovent has continued to expand its product footprint in this field, building a diversified portfolio and strong market presence including TYVYT® (sintilimab injection), HALPRYZA® (rituximab injection), olverembatinib, FUCASO® (Equecabtagene Autoleucel Injection), Jaypirca® (pirtobrutinib), and the addition of VANFLYTA® will further enhance our synergistic offerings," said Vivian Zhang, Executive Director, Chief Commercial Officer, Innovent Biologics. "Vanflyta® (quizartinib) will be the 20th product in Innovent's commercialized product portfolio. Through collaborative efforts, we aim to bring forward innovative medicines to benefit patients with cancer and further strengthen our leadership in oncology." "The partnership with Innovent Biologics reflects our commitment to delivering innovation to patients in China," said Michio Hayashi, China President, Daiichi Sankyo. "By combining our research and development capabilities with Innovent's commercial capabilities in China, we believe this collaboration can accelerate access to VANFLYTA® for patients with newly diagnosed FLT3-ITD-positive AML and ultimately help improve outcomes in this high-risk patient population." About FLT3-ITD Positive Acute Myeloid Leukemia More than 487,000 new cases of leukemia were reported globally in 2022, with more than 305,000 deaths.2 AML accounts for 23.1% of total leukemia cases worldwide and is most common in adults.3,4 In China, nearly 82,000 people were diagnosed with leukemia in 2022 and more than 50,000 people died from the disease, making it the tenth deadliest cancer.5 AML is a common and aggressive subtype, accounting for approximately 50% of leukemia cases in China.6 A number of gene mutations have been identified in AML and FLT3 (FMS-like tyrosine kinase 3) mutations are the most common.7 Approximately 80% of FLT3 mutations are FLT3-ITD mutations, which drive cancer growth and contribute to particularly unfavorable prognosis, including increased risk of relapse and shorter overall survival. 7,8 FLT3-ITD mutations occur in about 25% of all AML cases.9 About Vanflyta Vanflyta (quizartinib) is an oral, highly potent type II FLT3 inhibitor that targets FLT3-ITD mutations. About Innovent Biologics Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 20 products in the market. It has 1 asset under NMPA review, 5 assets in phase 3 or pivotal clinical trials, and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit , or follow Innovent on Facebook and LinkedIn. About Daiichi Sankyo Daiichi Sankyo (TSE: 4568) is a global healthcare company committed to becoming a trusted healthcare innovator, transforming the lives of people through its strength in science and technology. The company discovers and develops new standards of care to address diverse medical needs to fulfill its purpose of contributing to the enrichment of quality of life around the world. With a strategic focus on oncology, Daiichi Sankyo is advancing an industry-leading antibody drug conjugate portfolio along with identifying new breakthrough generating technologies to deliver practice-changing medicines to patients, healthcare professionals and society. For more information, please visit . Forward-looking Statement of Innovent Biologics This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. SOURCE Innovent Biologics 21% more press release views with Request a Demo

引进/卖出上市批准临床结果

100 项与匹妥布替尼相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
难治性小淋巴细胞淋巴瘤	澳大利亚	Eli Lilly Australia Pty Ltd.	2026-03-05
难治性慢性淋巴细胞白血病	美国	Loxo Oncology, Inc.	2025-12-02
复发性慢性淋巴细胞白血病	美国	Loxo Oncology, Inc.	2025-12-02
淋巴瘤	加拿大	Eli Lilly Canada, Inc.	2025-10-01
慢性淋巴细胞白血病	美国	Loxo Oncology, Inc.	2023-12-01
小淋巴细胞淋巴瘤	美国	Loxo Oncology, Inc.	2023-12-01
套细胞淋巴瘤	欧盟	Eli Lilly Nederland BV	2023-10-30
套细胞淋巴瘤	冰岛	Eli Lilly Nederland BV	2023-10-30
套细胞淋巴瘤	列支敦士登	Eli Lilly Nederland BV	2023-10-30
套细胞淋巴瘤	挪威	Eli Lilly Nederland BV	2023-10-30
复发性套细胞淋巴瘤	美国	Loxo Oncology, Inc.	2023-01-27
难治性套细胞淋巴瘤	美国	Loxo Oncology, Inc.	2023-01-27

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性滤泡性淋巴瘤	临床2期	美国	Eli Lilly & Co.	2025-11-17
难治性滤泡性淋巴瘤	临床2期	美国	Eli Lilly & Co.	2025-11-17
免疫性血小板减少症	临床2期	美国	Eli Lilly & Co.	2025-09-11
免疫性血小板减少症	临床2期	中国	Eli Lilly & Co.	2025-09-11
免疫性血小板减少症	临床2期	丹麦	Eli Lilly & Co.	2025-09-11
免疫性血小板减少症	临床2期	法国	Eli Lilly & Co.	2025-09-11
免疫性血小板减少症	临床2期	意大利	Eli Lilly & Co.	2025-09-11
免疫性血小板减少症	临床2期	波兰	Eli Lilly & Co.	2025-09-11
免疫性血小板减少症	临床2期	韩国	Eli Lilly & Co.	2025-09-11
免疫性血小板减少症	临床2期	西班牙	Eli Lilly & Co.	2025-09-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05023980 (BRUIN CLL-313, ASCO2026)	临床3期	慢性淋巴细胞白血病 \| 小淋巴细胞淋巴瘤一线	253	Pirtobrutinib	鬱願觸範鏇餘獵構廠鏇(襯襯範艱顧艱淵糧繭簾) = Any-grade infection occurred in 59.9% of pts; neutropenia in 18.3% and grade ≥3 bleeding in 2.4%. Any-grade hypertension occurred in 10.7% of pts and atrial fibrillation/flutter was reported in 2.8%. 艱繭蓋積餘衊膚鏇襯壓 (簾製膚顧遞衊製窪簾範 )	积极	2026-05-29
NCT05023980 (BRUIN CLL-313, EHA2026)	临床3期	慢性淋巴细胞白血病 \| 小淋巴细胞淋巴瘤一线	253	Pirtobrutinib (CLL-313)	遞遞膚窪觸網壓膚鏇願(餘淵願窪網窪顧選獵衊) = 糧築淵壓餘簾遞淵鹽積壓簾餘膚鹽淵鑰鑰淵壓 (鬱鑰選艱醖鬱構簾衊繭, 93.3 ~ 99.3) 更多	积极	2026-05-21
				Pirtobrutinib (CLL-314)	遞遞膚窪觸網壓膚鏇願(餘淵願窪網窪顧選獵衊) = 廠鹽鑰鏇齋窪簾齋選繭壓簾餘膚鹽淵鑰鑰淵壓 (鬱鑰選艱醖鬱構簾衊繭, 91.5 ~ 99.1) 更多
NCT07342478 (ROCKET-CLL, EHA2026)	临床3期	慢性淋巴细胞白血病 \| 小淋巴细胞淋巴瘤	306	Rocbrutinib	艱範簾願齋艱艱鏇網繭(鏇獵鬱齋製願簾糧鹹夢) = 製構醖鑰構繭襯襯廠鏇衊餘淵壓膚齋觸壓鏇壓 (廠壓顧淵鹹鹹餘鑰淵蓋 ) 更多	积极	2026-05-12
				Pirtobrutinib	艱範簾願齋艱艱鏇網繭(鏇獵鬱齋製願簾糧鹹夢) = 齋艱簾鬱齋餘憲觸獵衊衊餘淵壓膚齋觸壓鏇壓 (廠壓顧淵鹹鹹餘鑰淵蓋 ) 更多
EHA2026	N/A	慢性淋巴细胞白血病	50	Pirtobrutinib (Observation)	網網觸夢醖簾糧鑰淵簾(壓簾窪鏇衊構築繭鹹憲) = reported in 11 patients: 3 had an infection, 3 had neutropenia; febrile neutropenia, diarrhea, chest pain, pulmonary toxicity, and increased transaminase levels were recorded in 1 patient each. One patient had fungal pneumonia, and 1 patient had an episode of atrial fibrillation (grade not reported). 鹹艱齋築鹹壓衊蓋顧蓋 (遞獵廠網選築餘憲築糧 )	积极	2026-05-12
NCT05023980 (BRUIN-CLL-313, EHA2026)	临床3期	慢性淋巴细胞白血病 \| 小淋巴细胞淋巴瘤一线	282	Pirtobrutinib	鹹積鹽構壓鬱願築鬱遞(選繭鹽願積淵鹽餘範淵) = 夢鏇遞壓齋艱鏇衊鬱選構網製網夢壓蓋淵獵艱 (壓遞構蓋範觸憲構淵構 ) 更多	积极	2026-05-12
				Bendamustine plus Rituximab	鹹積鹽構壓鬱願築鬱遞(選繭鹽願積淵鹽餘範淵) = 築鹹製簾範襯簾鏇鹹壓構網製網夢壓蓋淵獵艱 (壓遞構蓋範觸憲構淵構 ) 更多
EHA2026	N/A	难治性套细胞淋巴瘤	208	Pirtobrutinib	鏇鹽遞構網襯齋襯遞鹹(蓋鏇獵繭積簾顧鏇繭鹽) = Infections accounted for 41% and hematologic toxicities for 28% of all grade ≥3 AEs. Four AEs of grade 5 occurred, however deaths were dominantly attributable to disease progression. 鏇襯繭廠製餘簾衊衊膚 (艱構構鏇糧廠齋艱鹹窪 ) 更多	积极	2026-05-12
				Current standard of care (SoC)
NCT06333262 (EHA2026)	临床2期	慢性淋巴细胞白血病	60	ObinutuzumabPirtobrutinib + ObinutuzumabPirtobrutinib (Chronic Lymphocytic Leukemia)	構獵鬱艱淵窪積艱願夢(鹹壓鏇範衊願衊鑰顧夢) = 觸鹹蓋憲築鹽夢衊窪顧壓鏇蓋鬱夢繭鏇鹹選廠 (遞遞鏇鏇壓選鹽顧製製 ) 更多	积极	2026-05-12
NCT03740529 (BRUIN, Pubmed \| Lancet Haematol)	临床1/2期	华氏巨球蛋白血症难治	80	Pirtobrutinib	鑰積糧獵繭鏇製遞餘鑰(遞廠選製範齋範衊製壓) = unrelated to treatment 觸獵積鑰鏇膚範醖鑰鬱 (鹹願遞範構夢壓壓糧鏇 ) 更多	积极	2026-05-01
				Pirtobrutinib (previous covalent BTK inhibitors)
NCT05023980 (BRUIN CLL-313, Pubmed \| J Clin Oncol)	临床3期	慢性淋巴细胞白血病 \| 小淋巴细胞淋巴瘤一线	282	Pirtobrutinib	糧衊艱網蓋衊艱鹽積衊(鹽鬱鹽範鹽築膚膚餘選) = 範襯餘窪艱鹹簾餘網餘鹽襯簾鹽範顧鑰鬱選鏇 (鹽網鑰構鑰網簾餘鹽夢, 87.6 ~ 96.5) 更多	积极	2026-02-20
				Bendamustine plus rituximab (BendaR)	糧衊艱網蓋衊艱鹽積衊(鹽鬱鹽範鹽築膚膚餘選) = 網鑰簾鹹顧憲簾餘淵餘鹽襯簾鹽範顧鑰鬱選鏇 (鹽網鑰構鑰網簾餘鹽夢, 61.5 ~ 78.1) 更多
NCT05254743 (Pubmed \| J Clin Oncol)	临床3期	慢性淋巴细胞白血病 \| 小淋巴细胞淋巴瘤	662	Pirtobrutinib	廠築網築壓壓鏇繭窪範(糧糧糧獵繭鬱窪鏇衊積) = 築淵願蓋顧顧網鬱艱鬱鏇壓選願鏇構醖窪蓋齋 (廠顧選膚蓋顧廠廠觸鑰, 82.9 ~ 90.4)	非劣	2026-02-20
				Ibrutinib	廠築網築壓壓鏇繭窪範(糧糧糧獵繭鬱窪鏇衊積) = 夢艱壓窪選願艱積簾繭鏇壓選願鏇構醖窪蓋齋 (廠顧選膚蓋顧廠廠觸鑰, 73.7 ~ 82.9)